Clin Pharmacol Ther ：2型糖尿病患者中GLP-1 RA和DPP-4抑制剂的使用与肠梗阻风险增加相关

2021-10-09 MedSci原创 MedSci原创

目前，我国上市的降糖药物种类约有10中，其中包括新型降糖药物二肽基肽酶-4(DPP-4)抑制剂，胰高血糖素样肽-1受体激动剂(GLP-1 RA)和钠-葡萄糖协同转运蛋白-2(SGLT-2)抑制剂等.

在糖尿病治疗探索过程中，很多大型研究发现，强化降糖可长期控制血糖水平，降低患者大血管、微血管并发症和糖尿病相关终点事件的发生风险。目前，我国上市的降糖药物种类约有10中，其中包括新型降糖药物二肽基肽酶-4(DPP-4)抑制剂，胰高血糖素样肽-1受体激动剂(GLP-1 RA)和钠-葡萄糖协同转运蛋白-2(SGLT-2)抑制剂等

胰高血糖素样肽-1受体激动剂(GLP-1 RA)和二肽基肽酶-4(DPP-4)抑制剂可能增加肠梗阻的风险，但缺乏该重度不良事件的真实证据。因此，本研究的目的是确定与钠-葡萄糖协同转运蛋白-2(SGLT-2)抑制剂相比，GLP-1 RA和DPP-4抑制剂是否与肠梗阻风险增加相关。

实验方法

我们使用英国临床实践研究数据链和链接数据库组装两个新使用者、活性对照队列(2013-2019)。第一项研究分别包括25,617和67,261例GLP-1 RA和SGLT-2抑制剂使用者。第二项研究分别纳入了131,927例和40,615例DPP-4抑制剂和SGLT-2抑制剂使用者。拟合倾向评分精细分层加权Cox比例风险模型，估计需要住院的肠梗阻的风险比(HR)和95%置信区间(CI)。

实验结果

与SGLT-2抑制剂相比，GLP-1 RA与肠梗阻风险增加相关（分别为1.9 vs. 1.1/1000人年；HR：1.69，95%CI：1.04-2.74）。使用1.6年后观察到最高HR(HR：3.48，95%CI：1.79-6.79)。DPP-4抑制剂也与肠梗阻风险增加相关（2.7 vs. 1.0/1000人年；HR：2.59，95%CI：1.52-4.42），使用1.8年后观察到最高HR(HR：9.53，95%CI：4.47-20.30)。GLP-1 RA和DPP-4抑制剂使用1年后需要伤害的数量分别为1223和603。

结论

在这项大型现实世界研究中，GLP-1 RA和DPP-4抑制剂与肠梗阻风险增加相关。

原文链接：https://pubmed.ncbi.nlm.nih.gov/34587280/

Incretin-Based Drugs and Risk of Intestinal Obstruction Among Patients with Type 2 Diabetes.

2021 Sep 29. doi: 10.1002/cpt.2430.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (12)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1788448, encodeId=f4bb1e88448f1, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu Sep 22 11:20:28 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787750, encodeId=62881e87750af, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Jan 21 19:20:28 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852770, encodeId=2f0b1852e70ae, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jul 15 09:20:28 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996434, encodeId=f5d81996434f8, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue May 24 16:20:28 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908663, encodeId=1bc5190866399, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Dec 17 04:20:28 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784712, encodeId=33b91e84712c0, content=<a href='/topic/show?id=6a926214b8' target=_blank style='color:#2F92EE;'>#DPP-4抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6214, encryptionId=6a926214b8, topicName=DPP-4抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Nov 30 17:20:28 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290111, encodeId=2a721290111a9, content=<a href='/topic/show?id=cea4815e119' target=_blank style='color:#2F92EE;'>#肠梗阻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81571, encryptionId=cea4815e119, topicName=肠梗阻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c950224, createdName=hjwang79, createdTime=Mon Oct 11 01:20:28 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374131, encodeId=477413e4131c9, content=<a href='/topic/show?id=dad4621545' target=_blank style='color:#2F92EE;'>#DPP-4抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6215, encryptionId=dad4621545, topicName=DPP-4抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8d7373, createdName=ewsr1, createdTime=Mon Oct 11 01:20:28 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383721, encodeId=05d41383e2166, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Mon Oct 11 01:20:28 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401968, encodeId=7e70140196829, content=<a href='/topic/show?id=7ff0621125' target=_blank style='color:#2F92EE;'>#DPP-4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6211, encryptionId=7ff0621125, topicName=DPP-4)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJmFzSicR3biaepTGaMtOl8hS8SjNQ92YP4GmFUlefPkcPnZJWBsHM057ogFrQEPrgdTgPrlxG70KYA/132, createdBy=eeb42370314, createdName=gaoxiaoe, createdTime=Mon Oct 11 01:20:28 CST 2021, time=2021-10-11, status=1, ipAttribution=)]
2022-09-22 dingxiaobo

#Pharmacol#

96 0
[GetPortalCommentsPageByObjectIdResponse(id=1788448, encodeId=f4bb1e88448f1, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu Sep 22 11:20:28 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787750, encodeId=62881e87750af, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Jan 21 19:20:28 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852770, encodeId=2f0b1852e70ae, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jul 15 09:20:28 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996434, encodeId=f5d81996434f8, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue May 24 16:20:28 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908663, encodeId=1bc5190866399, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Dec 17 04:20:28 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784712, encodeId=33b91e84712c0, content=<a href='/topic/show?id=6a926214b8' target=_blank style='color:#2F92EE;'>#DPP-4抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6214, encryptionId=6a926214b8, topicName=DPP-4抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Nov 30 17:20:28 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290111, encodeId=2a721290111a9, content=<a href='/topic/show?id=cea4815e119' target=_blank style='color:#2F92EE;'>#肠梗阻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81571, encryptionId=cea4815e119, topicName=肠梗阻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c950224, createdName=hjwang79, createdTime=Mon Oct 11 01:20:28 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374131, encodeId=477413e4131c9, content=<a href='/topic/show?id=dad4621545' target=_blank style='color:#2F92EE;'>#DPP-4抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6215, encryptionId=dad4621545, topicName=DPP-4抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8d7373, createdName=ewsr1, createdTime=Mon Oct 11 01:20:28 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383721, encodeId=05d41383e2166, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Mon Oct 11 01:20:28 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401968, encodeId=7e70140196829, content=<a href='/topic/show?id=7ff0621125' target=_blank style='color:#2F92EE;'>#DPP-4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6211, encryptionId=7ff0621125, topicName=DPP-4)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJmFzSicR3biaepTGaMtOl8hS8SjNQ92YP4GmFUlefPkcPnZJWBsHM057ogFrQEPrgdTgPrlxG70KYA/132, createdBy=eeb42370314, createdName=gaoxiaoe, createdTime=Mon Oct 11 01:20:28 CST 2021, time=2021-10-11, status=1, ipAttribution=)]
2022-01-21 jj000001

#Pharm#

68 0
[GetPortalCommentsPageByObjectIdResponse(id=1788448, encodeId=f4bb1e88448f1, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu Sep 22 11:20:28 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787750, encodeId=62881e87750af, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Jan 21 19:20:28 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852770, encodeId=2f0b1852e70ae, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jul 15 09:20:28 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996434, encodeId=f5d81996434f8, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue May 24 16:20:28 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908663, encodeId=1bc5190866399, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Dec 17 04:20:28 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784712, encodeId=33b91e84712c0, content=<a href='/topic/show?id=6a926214b8' target=_blank style='color:#2F92EE;'>#DPP-4抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6214, encryptionId=6a926214b8, topicName=DPP-4抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Nov 30 17:20:28 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290111, encodeId=2a721290111a9, content=<a href='/topic/show?id=cea4815e119' target=_blank style='color:#2F92EE;'>#肠梗阻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81571, encryptionId=cea4815e119, topicName=肠梗阻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c950224, createdName=hjwang79, createdTime=Mon Oct 11 01:20:28 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374131, encodeId=477413e4131c9, content=<a href='/topic/show?id=dad4621545' target=_blank style='color:#2F92EE;'>#DPP-4抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6215, encryptionId=dad4621545, topicName=DPP-4抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8d7373, createdName=ewsr1, createdTime=Mon Oct 11 01:20:28 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383721, encodeId=05d41383e2166, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Mon Oct 11 01:20:28 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401968, encodeId=7e70140196829, content=<a href='/topic/show?id=7ff0621125' target=_blank style='color:#2F92EE;'>#DPP-4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6211, encryptionId=7ff0621125, topicName=DPP-4)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJmFzSicR3biaepTGaMtOl8hS8SjNQ92YP4GmFUlefPkcPnZJWBsHM057ogFrQEPrgdTgPrlxG70KYA/132, createdBy=eeb42370314, createdName=gaoxiaoe, createdTime=Mon Oct 11 01:20:28 CST 2021, time=2021-10-11, status=1, ipAttribution=)]
2022-07-15 jklm09

#抑制剂#

75 0
[GetPortalCommentsPageByObjectIdResponse(id=1788448, encodeId=f4bb1e88448f1, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu Sep 22 11:20:28 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787750, encodeId=62881e87750af, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Jan 21 19:20:28 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852770, encodeId=2f0b1852e70ae, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jul 15 09:20:28 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996434, encodeId=f5d81996434f8, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue May 24 16:20:28 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908663, encodeId=1bc5190866399, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Dec 17 04:20:28 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784712, encodeId=33b91e84712c0, content=<a href='/topic/show?id=6a926214b8' target=_blank style='color:#2F92EE;'>#DPP-4抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6214, encryptionId=6a926214b8, topicName=DPP-4抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Nov 30 17:20:28 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290111, encodeId=2a721290111a9, content=<a href='/topic/show?id=cea4815e119' target=_blank style='color:#2F92EE;'>#肠梗阻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81571, encryptionId=cea4815e119, topicName=肠梗阻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c950224, createdName=hjwang79, createdTime=Mon Oct 11 01:20:28 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374131, encodeId=477413e4131c9, content=<a href='/topic/show?id=dad4621545' target=_blank style='color:#2F92EE;'>#DPP-4抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6215, encryptionId=dad4621545, topicName=DPP-4抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8d7373, createdName=ewsr1, createdTime=Mon Oct 11 01:20:28 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383721, encodeId=05d41383e2166, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Mon Oct 11 01:20:28 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401968, encodeId=7e70140196829, content=<a href='/topic/show?id=7ff0621125' target=_blank style='color:#2F92EE;'>#DPP-4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6211, encryptionId=7ff0621125, topicName=DPP-4)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJmFzSicR3biaepTGaMtOl8hS8SjNQ92YP4GmFUlefPkcPnZJWBsHM057ogFrQEPrgdTgPrlxG70KYA/132, createdBy=eeb42370314, createdName=gaoxiaoe, createdTime=Mon Oct 11 01:20:28 CST 2021, time=2021-10-11, status=1, ipAttribution=)]
2022-05-24 yb6560

#MAC#

73 0
[GetPortalCommentsPageByObjectIdResponse(id=1788448, encodeId=f4bb1e88448f1, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu Sep 22 11:20:28 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787750, encodeId=62881e87750af, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Jan 21 19:20:28 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852770, encodeId=2f0b1852e70ae, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jul 15 09:20:28 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996434, encodeId=f5d81996434f8, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue May 24 16:20:28 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908663, encodeId=1bc5190866399, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Dec 17 04:20:28 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784712, encodeId=33b91e84712c0, content=<a href='/topic/show?id=6a926214b8' target=_blank style='color:#2F92EE;'>#DPP-4抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6214, encryptionId=6a926214b8, topicName=DPP-4抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Nov 30 17:20:28 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290111, encodeId=2a721290111a9, content=<a href='/topic/show?id=cea4815e119' target=_blank style='color:#2F92EE;'>#肠梗阻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81571, encryptionId=cea4815e119, topicName=肠梗阻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c950224, createdName=hjwang79, createdTime=Mon Oct 11 01:20:28 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374131, encodeId=477413e4131c9, content=<a href='/topic/show?id=dad4621545' target=_blank style='color:#2F92EE;'>#DPP-4抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6215, encryptionId=dad4621545, topicName=DPP-4抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8d7373, createdName=ewsr1, createdTime=Mon Oct 11 01:20:28 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383721, encodeId=05d41383e2166, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Mon Oct 11 01:20:28 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401968, encodeId=7e70140196829, content=<a href='/topic/show?id=7ff0621125' target=_blank style='color:#2F92EE;'>#DPP-4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6211, encryptionId=7ff0621125, topicName=DPP-4)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJmFzSicR3biaepTGaMtOl8hS8SjNQ92YP4GmFUlefPkcPnZJWBsHM057ogFrQEPrgdTgPrlxG70KYA/132, createdBy=eeb42370314, createdName=gaoxiaoe, createdTime=Mon Oct 11 01:20:28 CST 2021, time=2021-10-11, status=1, ipAttribution=)]
2021-12-17 chentianping

#pharma#

65 0
[GetPortalCommentsPageByObjectIdResponse(id=1788448, encodeId=f4bb1e88448f1, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu Sep 22 11:20:28 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787750, encodeId=62881e87750af, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Jan 21 19:20:28 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852770, encodeId=2f0b1852e70ae, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jul 15 09:20:28 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996434, encodeId=f5d81996434f8, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue May 24 16:20:28 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908663, encodeId=1bc5190866399, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Dec 17 04:20:28 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784712, encodeId=33b91e84712c0, content=<a href='/topic/show?id=6a926214b8' target=_blank style='color:#2F92EE;'>#DPP-4抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6214, encryptionId=6a926214b8, topicName=DPP-4抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Nov 30 17:20:28 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290111, encodeId=2a721290111a9, content=<a href='/topic/show?id=cea4815e119' target=_blank style='color:#2F92EE;'>#肠梗阻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81571, encryptionId=cea4815e119, topicName=肠梗阻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c950224, createdName=hjwang79, createdTime=Mon Oct 11 01:20:28 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374131, encodeId=477413e4131c9, content=<a href='/topic/show?id=dad4621545' target=_blank style='color:#2F92EE;'>#DPP-4抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6215, encryptionId=dad4621545, topicName=DPP-4抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8d7373, createdName=ewsr1, createdTime=Mon Oct 11 01:20:28 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383721, encodeId=05d41383e2166, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Mon Oct 11 01:20:28 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401968, encodeId=7e70140196829, content=<a href='/topic/show?id=7ff0621125' target=_blank style='color:#2F92EE;'>#DPP-4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6211, encryptionId=7ff0621125, topicName=DPP-4)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJmFzSicR3biaepTGaMtOl8hS8SjNQ92YP4GmFUlefPkcPnZJWBsHM057ogFrQEPrgdTgPrlxG70KYA/132, createdBy=eeb42370314, createdName=gaoxiaoe, createdTime=Mon Oct 11 01:20:28 CST 2021, time=2021-10-11, status=1, ipAttribution=)]
2021-11-30 xue8602

#DPP-4抑制#

73 0
[GetPortalCommentsPageByObjectIdResponse(id=1788448, encodeId=f4bb1e88448f1, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu Sep 22 11:20:28 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787750, encodeId=62881e87750af, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Jan 21 19:20:28 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852770, encodeId=2f0b1852e70ae, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jul 15 09:20:28 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996434, encodeId=f5d81996434f8, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue May 24 16:20:28 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908663, encodeId=1bc5190866399, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Dec 17 04:20:28 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784712, encodeId=33b91e84712c0, content=<a href='/topic/show?id=6a926214b8' target=_blank style='color:#2F92EE;'>#DPP-4抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6214, encryptionId=6a926214b8, topicName=DPP-4抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Nov 30 17:20:28 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290111, encodeId=2a721290111a9, content=<a href='/topic/show?id=cea4815e119' target=_blank style='color:#2F92EE;'>#肠梗阻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81571, encryptionId=cea4815e119, topicName=肠梗阻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c950224, createdName=hjwang79, createdTime=Mon Oct 11 01:20:28 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374131, encodeId=477413e4131c9, content=<a href='/topic/show?id=dad4621545' target=_blank style='color:#2F92EE;'>#DPP-4抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6215, encryptionId=dad4621545, topicName=DPP-4抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8d7373, createdName=ewsr1, createdTime=Mon Oct 11 01:20:28 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383721, encodeId=05d41383e2166, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Mon Oct 11 01:20:28 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401968, encodeId=7e70140196829, content=<a href='/topic/show?id=7ff0621125' target=_blank style='color:#2F92EE;'>#DPP-4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6211, encryptionId=7ff0621125, topicName=DPP-4)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJmFzSicR3biaepTGaMtOl8hS8SjNQ92YP4GmFUlefPkcPnZJWBsHM057ogFrQEPrgdTgPrlxG70KYA/132, createdBy=eeb42370314, createdName=gaoxiaoe, createdTime=Mon Oct 11 01:20:28 CST 2021, time=2021-10-11, status=1, ipAttribution=)]
2021-10-11 hjwang79

#肠梗阻#

117 0
[GetPortalCommentsPageByObjectIdResponse(id=1788448, encodeId=f4bb1e88448f1, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu Sep 22 11:20:28 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787750, encodeId=62881e87750af, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Jan 21 19:20:28 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852770, encodeId=2f0b1852e70ae, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jul 15 09:20:28 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996434, encodeId=f5d81996434f8, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue May 24 16:20:28 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908663, encodeId=1bc5190866399, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Dec 17 04:20:28 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784712, encodeId=33b91e84712c0, content=<a href='/topic/show?id=6a926214b8' target=_blank style='color:#2F92EE;'>#DPP-4抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6214, encryptionId=6a926214b8, topicName=DPP-4抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Nov 30 17:20:28 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290111, encodeId=2a721290111a9, content=<a href='/topic/show?id=cea4815e119' target=_blank style='color:#2F92EE;'>#肠梗阻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81571, encryptionId=cea4815e119, topicName=肠梗阻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c950224, createdName=hjwang79, createdTime=Mon Oct 11 01:20:28 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374131, encodeId=477413e4131c9, content=<a href='/topic/show?id=dad4621545' target=_blank style='color:#2F92EE;'>#DPP-4抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6215, encryptionId=dad4621545, topicName=DPP-4抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8d7373, createdName=ewsr1, createdTime=Mon Oct 11 01:20:28 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383721, encodeId=05d41383e2166, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Mon Oct 11 01:20:28 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401968, encodeId=7e70140196829, content=<a href='/topic/show?id=7ff0621125' target=_blank style='color:#2F92EE;'>#DPP-4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6211, encryptionId=7ff0621125, topicName=DPP-4)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJmFzSicR3biaepTGaMtOl8hS8SjNQ92YP4GmFUlefPkcPnZJWBsHM057ogFrQEPrgdTgPrlxG70KYA/132, createdBy=eeb42370314, createdName=gaoxiaoe, createdTime=Mon Oct 11 01:20:28 CST 2021, time=2021-10-11, status=1, ipAttribution=)]
2021-10-11 ewsr1

#DPP-4抑制剂#

90 0
[GetPortalCommentsPageByObjectIdResponse(id=1788448, encodeId=f4bb1e88448f1, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu Sep 22 11:20:28 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787750, encodeId=62881e87750af, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Jan 21 19:20:28 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852770, encodeId=2f0b1852e70ae, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jul 15 09:20:28 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996434, encodeId=f5d81996434f8, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue May 24 16:20:28 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908663, encodeId=1bc5190866399, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Dec 17 04:20:28 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784712, encodeId=33b91e84712c0, content=<a href='/topic/show?id=6a926214b8' target=_blank style='color:#2F92EE;'>#DPP-4抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6214, encryptionId=6a926214b8, topicName=DPP-4抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Nov 30 17:20:28 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290111, encodeId=2a721290111a9, content=<a href='/topic/show?id=cea4815e119' target=_blank style='color:#2F92EE;'>#肠梗阻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81571, encryptionId=cea4815e119, topicName=肠梗阻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c950224, createdName=hjwang79, createdTime=Mon Oct 11 01:20:28 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374131, encodeId=477413e4131c9, content=<a href='/topic/show?id=dad4621545' target=_blank style='color:#2F92EE;'>#DPP-4抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6215, encryptionId=dad4621545, topicName=DPP-4抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8d7373, createdName=ewsr1, createdTime=Mon Oct 11 01:20:28 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383721, encodeId=05d41383e2166, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Mon Oct 11 01:20:28 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401968, encodeId=7e70140196829, content=<a href='/topic/show?id=7ff0621125' target=_blank style='color:#2F92EE;'>#DPP-4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6211, encryptionId=7ff0621125, topicName=DPP-4)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJmFzSicR3biaepTGaMtOl8hS8SjNQ92YP4GmFUlefPkcPnZJWBsHM057ogFrQEPrgdTgPrlxG70KYA/132, createdBy=eeb42370314, createdName=gaoxiaoe, createdTime=Mon Oct 11 01:20:28 CST 2021, time=2021-10-11, status=1, ipAttribution=)]
2021-10-11 aids213

#2型糖尿病患者#

57 0
[GetPortalCommentsPageByObjectIdResponse(id=1788448, encodeId=f4bb1e88448f1, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu Sep 22 11:20:28 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787750, encodeId=62881e87750af, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Jan 21 19:20:28 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852770, encodeId=2f0b1852e70ae, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jul 15 09:20:28 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996434, encodeId=f5d81996434f8, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue May 24 16:20:28 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908663, encodeId=1bc5190866399, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Dec 17 04:20:28 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784712, encodeId=33b91e84712c0, content=<a href='/topic/show?id=6a926214b8' target=_blank style='color:#2F92EE;'>#DPP-4抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6214, encryptionId=6a926214b8, topicName=DPP-4抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Nov 30 17:20:28 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290111, encodeId=2a721290111a9, content=<a href='/topic/show?id=cea4815e119' target=_blank style='color:#2F92EE;'>#肠梗阻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81571, encryptionId=cea4815e119, topicName=肠梗阻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c950224, createdName=hjwang79, createdTime=Mon Oct 11 01:20:28 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374131, encodeId=477413e4131c9, content=<a href='/topic/show?id=dad4621545' target=_blank style='color:#2F92EE;'>#DPP-4抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6215, encryptionId=dad4621545, topicName=DPP-4抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8d7373, createdName=ewsr1, createdTime=Mon Oct 11 01:20:28 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383721, encodeId=05d41383e2166, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Mon Oct 11 01:20:28 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401968, encodeId=7e70140196829, content=<a href='/topic/show?id=7ff0621125' target=_blank style='color:#2F92EE;'>#DPP-4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6211, encryptionId=7ff0621125, topicName=DPP-4)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJmFzSicR3biaepTGaMtOl8hS8SjNQ92YP4GmFUlefPkcPnZJWBsHM057ogFrQEPrgdTgPrlxG70KYA/132, createdBy=eeb42370314, createdName=gaoxiaoe, createdTime=Mon Oct 11 01:20:28 CST 2021, time=2021-10-11, status=1, ipAttribution=)]
2021-10-11 gaoxiaoe

#DPP-4#

69 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

内分泌科

Clin Pharmacol Ther ：2型糖尿病患者中GLP-1 RA和DPP-4抑制剂的使用与肠梗阻风险增加相关

相关资讯

拓展阅读

科室

工具

服务